<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01909141</url>
  </required_header>
  <id_info>
    <org_study_id>fem2013</org_study_id>
    <nct_id>NCT01909141</nct_id>
  </id_info>
  <brief_title>Ovulation Induction in Women With Clomiphene Citrate Resistant PCOS</brief_title>
  <official_title>Combined Letrozole-metformin-pioglitazone Versus Combined Clomiphene Citrate-metformin-pioglitazone in Clomiphene Citrate-resistant Women With Polycystic Ovary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <brief_summary>
    <textblock>
      Polycystic ovary syndrome (PCOS) affects 5-10% of women in childbearing age. Hyperinsulinemia
      contributes to chronic anovulation commonly encountered in women with PCOS. The first choice
      therapy is clomiphene citrate (CC). In CC resistant cases, the American College of Obstetrics
      and Gynecology (ACOG) recommends the use of insulin sensitizer metformin. Other insulin
      sensitizing agents include rosiglitazone and pioglitazone. Pioglitazone is said to improve
      fertility and ovulation in patients with PCOS.CC may be associated with poor endometrial
      thickening due to its antiestrogenic effect. Letrozole may improve this condition. In this
      study we will compare the effect of combined letrozole-metformin-pioglitazone with that of
      combined CC-metformin-pioglitazone in ovulation induction in CC-resistant PCOS women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Polycystic ovary syndrome (PCOS) affects 5-10% of women in childbearing age. Hyperinsulinemia
      contributes to chronic anovulation commonly encountered in women with PCOS. The first choice
      therapy is clomiphene citrate (CC). In CC resistant cases, the ACOG recommends the use of
      insulin sensitizer metformin. Other insulin sensitizing agents include rosiglitazone and
      pioglitazone. Pioglitazone is said to improve fertility and ovulation in patients with
      PCOS.CC has a long half-life (2 weeks), and this may have a negative effect on the cervical
      mucus and endometrium, leading to discrepancy between ovulation and conception rates. There
      has been a search for a compound capable of inducing ovulation but devoid of the adverse
      antiestrogenic effects of CC. recent studies have suggested that letrozole, an aromatase
      inhibitor, does not possess the adverse antiestrogenic effects of CC and is associated with
      higher pregnancy rates than CC treatment in patients with PCOS.

      In this study we shall compare the effect of combined letrozole-metformin-pioglitazone with
      that of combined CC-metformin-pioglitazone in ovulation induction in CC-resistant PCOS
      women.This will be a prospective comparative clinical trial in which 2 groups of women will
      be generated (groups A and B) using the sealed envelopes randomization method.Group A (40
      women) will receive: letrozole 2.5 mg/day from 3rd day of the cycle for 5 days and
      (pioglitazone 15 mg + metformin 850 mg) once daily from 1st day of the cycle for 10 days.
      Group B (40 women) will receive clomiphene citrate 100 mg/day from 3rd day of the cycle for 5
      days and (pioglitazone 15 mg + metformin 850 mg) once daily from 1st day of the cycle for 10
      days. Ovulation will be monitored by vaginal ultrasound and serum estrogen and progesterone.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ovulation Rate</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Follicles&gt;18mm.</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endometrial Thickness</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy Rate</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety of Pioglitazone as Regards Serum Creatinine</measure>
    <time_frame>3 months</time_frame>
    <description>serum creatinine was measured at the end of the study period (after 3 months) in both groups.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>arm 1:letrozole-pioglitazone -metformin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 1 will receive letrozole 2.5 mg/day starting from the 3rd day of the cycle and for 5 days and (combined pioglitazone 15 mg+ metformin 850 mg) once daily from the first day of the cycle for 10 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>arm 2: clomiphene citrate-pioglitazone-metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 2 will receive clomiphene citrate 100 mg/day starting from the 3rd day of the cycle for 5 days and (combined pioglitazone 15 mg + metformin 850 mg) once daily from the first day of the cycle for 10 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>induction of ovulation using letrozole-pioglitazone-metformin</intervention_name>
    <description>induction of ovulation will be done for arm 1 for 3 consecutive cycles unless pregnancy occured.</description>
    <arm_group_label>arm 1:letrozole-pioglitazone -metformin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>induction of ovulation using clomiphene citrate-pioglitazone-metformin</intervention_name>
    <description>induction of ovulation for arm 2 will be done in 3 consecutive cycles unless pregnancy occured.</description>
    <arm_group_label>arm 2: clomiphene citrate-pioglitazone-metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>transvaginal ultrasound</intervention_name>
    <description>transvaginal ultrasound will be done starting from day 10 and every 48 hours until finding a follicle of &gt; 18 mm or till day 20 of the cycle</description>
    <arm_group_label>arm 1:letrozole-pioglitazone -metformin group</arm_group_label>
    <arm_group_label>arm 2: clomiphene citrate-pioglitazone-metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>body mass index (BMI) calculation</intervention_name>
    <description>BMI will be calculated for all women by dividing the weight in kilograms by the height in meters squared</description>
    <arm_group_label>arm 1:letrozole-pioglitazone -metformin group</arm_group_label>
    <arm_group_label>arm 2: clomiphene citrate-pioglitazone-metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>day 3: follicle stimulating hormone (FSH), luteinizing hormone (LH), thyroid stimulating hormone (TSH), total testosterone</intervention_name>
    <description>baseline hormonal assay (day 3 FSH, LH, TSH and total testosterone) will be done for all women.</description>
    <arm_group_label>arm 1:letrozole-pioglitazone -metformin group</arm_group_label>
    <arm_group_label>arm 2: clomiphene citrate-pioglitazone-metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pretreatment blood urea and serum creatinine</intervention_name>
    <description>blood urea and serum creatinine will be assayed before stating induction of ovulation to have baseline levels.</description>
    <arm_group_label>arm 1:letrozole-pioglitazone -metformin group</arm_group_label>
    <arm_group_label>arm 2: clomiphene citrate-pioglitazone-metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>serum estradiol (E2) on day 12</intervention_name>
    <description>serum E2 will be assayed on day 12 of the cycle for all women.</description>
    <arm_group_label>arm 1:letrozole-pioglitazone -metformin group</arm_group_label>
    <arm_group_label>arm 2: clomiphene citrate-pioglitazone-metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>serum progesterone on day 21</intervention_name>
    <description>serum progesterone will be assayed on day 21 for all women to monitor ovulation.</description>
    <arm_group_label>arm 1:letrozole-pioglitazone -metformin group</arm_group_label>
    <arm_group_label>arm 2: clomiphene citrate-pioglitazone-metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood urea and serum creatinine every month</intervention_name>
    <description>blood urea and serum creatinine will be assayed every month during the treatment period to find out any hazards on kidney functions</description>
    <arm_group_label>arm 1:letrozole-pioglitazone -metformin group</arm_group_label>
    <arm_group_label>arm 2: clomiphene citrate-pioglitazone-metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  20-40 years old

          -  PCOS infertile women resistant to CC for3 cycles

        Exclusion Criteria:

          -  presence of medical disorders as diabetes, hypertension, cardiac problems, liver or
             kidney diseases, hyperprolactinemia or thyroid dysfunction.

          -  use of gonadotropins before

          -  previous ovarian drilling

          -  presence of urinary symptoms especially bloody urine
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ghada Abdel Fattah Abdel Moety, lecturer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cairo University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2013</study_first_submitted>
  <study_first_submitted_qc>July 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2013</study_first_posted>
  <results_first_submitted>February 3, 2015</results_first_submitted>
  <results_first_submitted_qc>February 19, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 2, 2015</results_first_posted>
  <last_update_submitted>September 30, 2015</last_update_submitted>
  <last_update_submitted_qc>September 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Ghada Abdel Fattah</investigator_full_name>
    <investigator_title>lecturer of Obstetrics and Gynecology-Cairo University</investigator_title>
  </responsible_party>
  <keyword>letrozole</keyword>
  <keyword>clomiphene citrate</keyword>
  <keyword>pioglitazone</keyword>
  <keyword>metformin</keyword>
  <keyword>ovulation induction</keyword>
  <keyword>PCOS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Follicle Stimulating Hormone</mesh_term>
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Clomiphene</mesh_term>
    <mesh_term>Enclomiphene</mesh_term>
    <mesh_term>Zuclomiphene</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm 1:Letrozole-pioglitazone -Metformin Group</title>
          <description>Arm 1 received letrozole 2.5 mg/day starting from the 3rd day of the cycle and for 5 days and (combined pioglitazone 15 mg+ metformin 850 mg) once daily from the first day of the cycle for 10 days.
induction of ovulation using letrozole-pioglitazone-metformin: induction of ovulation was done for arm 1 for 3 consecutive cycles unless pregnancy occurred.
transvaginal ultrasound: transvaginal ultrasound will be done starting from day 10 and every 48 hours until finding a follicle of &gt; 18 mm or till day 20 of the cycle
body mass index (BMI) calculation: BMI was calculated.
day 3: follicle stimulating hormone (FSH), luteinizing hormone (LH), thyroid stimulating hormone (TSH), total testosterone: baseline hormonal assay (day 3 FSH, LH, TSH and total testosterone) were done for all women.
serum estradiol (E2) was done on day of hCG administration for all women.
serum progesterone on day 21 was done for all women.</description>
        </group>
        <group group_id="P2">
          <title>Arm 2: Clomiphene Citrate-pioglitazone-metformin</title>
          <description>Arm 2 received clomiphene citrate 100 mg/day starting from the 3rd day of the cycle for 5 days and (combined pioglitazone 15 mg + metformin 850 mg) once daily from the first day of the cycle for 10 days.
induction of ovulation using clomiphene citrate-pioglitazone-metformin: induction of ovulation for arm 2 was done in 3 consecutive cycles unless pregnancy occurred.
transvaginal ultrasound: transvaginal ultrasound was done starting from day 10 and every 48 hours until finding a follicle of &gt; 18 mm or till day 20 of the cycle
body mass index (BMI) calculation: BMI was calculated.
day 3: follicle stimulating hormone (FSH), luteinizing hormone (LH), thyroid stimulating hormone (TSH), total testosterone: baseline hormonal assay (day 3 FSH, LH, TSH and total testosterone) were done for all women.
serum estradiol (E2) was done on day of hCG administration for all women.
serum progesterone on day 21 was done for all women.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1:Letrozole-pioglitazone -Metformin Group</title>
          <description>Arm 1 received letrozole 2.5 mg/day starting from the 3rd day of the cycle and for 5 days and (combined pioglitazone 15 mg+ metformin 850 mg) once daily from the first day of the cycle for 10 days.
induction of ovulation using letrozole-pioglitazone-metformin: induction of ovulation was done for arm 1 for 3 consecutive cycles unless pregnancy occurred.
transvaginal ultrasound: transvaginal ultrasound was done starting from day 10 and every 48 hours until finding a follicle of &gt; 18 mm or till day 20 of the cycle
body mass index (BMI) calculation: BMI was calculated.
day 3: follicle stimulating hormone (FSH), luteinizing hormone (LH), thyroid stimulating hormone (TSH), total testosterone: baseline hormonal assay (day 3 FSH, LH, TSH and total testosterone) were done for all women.
serum estradiol (E2) was done on day of hCG administration for all women.
serum progesterone on day 21 was done for all women.</description>
        </group>
        <group group_id="B2">
          <title>Arm 2: Clomiphene Citrate-pioglitazone-metformin</title>
          <description>Arm 2 will received clomiphene citrate 100 mg/day starting from the 3rd day of the cycle for 5 days and (combined pioglitazone 15 mg + metformin 850 mg) once daily from the first day of the cycle for 10 days.
induction of ovulation using clomiphene citrate-pioglitazone-metformin: induction of ovulation for arm 2 was done in 3 consecutive cycles unless pregnancy occured.
transvaginal ultrasound: transvaginal ultrasound was done starting from day 10 and every 48 hours until finding a follicle of &gt; 18 mm or till day 20 of the cycle
body mass index (BMI) calculation: BMI was calculated.
day 3: follicle stimulating hormone (FSH), luteinizing hormone (LH), thyroid stimulating hormone (TSH), total testosterone: baseline hormonal assay (day 3 FSH, LH, TSH and total testosterone) were done for all women.
serum estradiol (E2) was done on day of hCG administration for all women.
serum progesterone on day 21 was done for all women.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.8" spread="3.62"/>
                    <measurement group_id="B2" value="26.58" spread="2.9"/>
                    <measurement group_id="B3" value="26.19" spread="3.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Egypt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>infertility period</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.67" spread="1.62"/>
                    <measurement group_id="B2" value="3.07" spread="1.46"/>
                    <measurement group_id="B3" value="2.87" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.45" spread="2.84"/>
                    <measurement group_id="B2" value="26.57" spread="2.7"/>
                    <measurement group_id="B3" value="26.51" spread="2.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>waist/hip ratio</title>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.838" spread="0.02"/>
                    <measurement group_id="B2" value="0.837" spread="0.04"/>
                    <measurement group_id="B3" value="0.837" spread="0.037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>systolic blood pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106.08" spread="8.81"/>
                    <measurement group_id="B2" value="107.04" spread="8.97"/>
                    <measurement group_id="B3" value="106.56" spread="8.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>diastolic blood pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.6" spread="5.31"/>
                    <measurement group_id="B2" value="68.44" spread="5.89"/>
                    <measurement group_id="B3" value="69.02" spread="5.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>hirsutism</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>acne</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ovarian volume</title>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.17" spread="0.76"/>
                    <measurement group_id="B2" value="14.58" spread="1.42"/>
                    <measurement group_id="B3" value="14.19" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FSH</title>
          <units>mIU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.71" spread="1.34"/>
                    <measurement group_id="B2" value="5.68" spread="1.38"/>
                    <measurement group_id="B3" value="5.7" spread="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LH</title>
          <units>mIU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.81" spread="3.16"/>
                    <measurement group_id="B2" value="10.55" spread="3.25"/>
                    <measurement group_id="B3" value="10.18" spread="3.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>E2</title>
          <units>Pmol/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.83" spread="7.31"/>
                    <measurement group_id="B2" value="47.75" spread="10.02"/>
                    <measurement group_id="B3" value="48.24" spread="8.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>prolactin</title>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.52" spread="4.84"/>
                    <measurement group_id="B2" value="14.3" spread="5.6"/>
                    <measurement group_id="B3" value="14.9" spread="5.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>total testosterone</title>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.19" spread="0.25"/>
                    <measurement group_id="B2" value="1.13" spread="0.2"/>
                    <measurement group_id="B3" value="1.16" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>free testosterone</title>
          <units>Pmol/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.87" spread="0.61"/>
                    <measurement group_id="B2" value="4.12" spread="1.17"/>
                    <measurement group_id="B3" value="3.99" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>TSH</title>
          <units>mIU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.42" spread="0.61"/>
                    <measurement group_id="B2" value="3.51" spread="0.44"/>
                    <measurement group_id="B3" value="3.47" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>free T4</title>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.78" spread="0.84"/>
                    <measurement group_id="B2" value="13.58" spread="0.45"/>
                    <measurement group_id="B3" value="13.68" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ovulation Rate</title>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1:Letrozole-pioglitazone -Metformin Group</title>
            <description>Arm 1 receivde letrozole 2.5 mg/day starting from the 3rd day of the cycle and for 5 days and (combined pioglitazone 15 mg+ metformin 850 mg) once daily from the first day of the cycle for 10 days.
induction of ovulation using letrozole-pioglitazone-metformin: induction of ovulation was be done for arm 1 for 3 consecutive cycles unless pregnancy occured.
transvaginal ultrasound: transvaginal ultrasound was done starting from day 10 and every 48 hours until finding a follicle of &gt; 18 mm or till day 20 of the cycle
body mass index (BMI) calculation: BMI was caculated.
day 3: follicle stimulating hormone (FSH), luteinizing hormone (LH), thyroid stimulating hormone (TSH), total testosterone: baseline hormonal assay (day 3 FSH, LH, TSH and total testosterone) were done for all women.
serum estradiol (E2) was done on day of hCG administration for all women.
serum progesterone on day 21 was done for all women.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Clomiphene Citrate-pioglitazone-metformin</title>
            <description>Arm 2 received clomiphene citrate 100 mg/day starting from the 3rd day of the cycle for 5 days and (combined pioglitazone 15 mg + metformin 850 mg) once daily from the first day of the cycle for 10 days.
induction of ovulation using clomiphene citrate-pioglitazone-metformin: induction of ovulation for arm 2 was done in 3 consecutive cycles unless pregnancy occured.
transvaginal ultrasound: transvaginal ultrasound was done starting from day 10 and every 48 hours until finding a follicle of &gt; 18 mm or till day 20 of the cycle
body mass index (BMI) calculation: BMI was calculated
day 3: follicle stimulating hormone (FSH), luteinizing hormone (LH), thyroid stimulating hormone (TSH), total testosterone: baseline hormonal assay (day 3 FSH, LH, TSH and total testosterone) were done for all women.
serum estradiol (E2) was done on day of hCG administration for all women.
serum progesterone on day 21 was done for all women.</description>
          </group>
        </group_list>
        <measure>
          <title>Ovulation Rate</title>
          <units>percentage of all cycles</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Follicles&gt;18mm.</title>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1:Letrozole-pioglitazone -Metformin Group</title>
            <description>Arm 1 received letrozole 2.5 mg/day starting from the 3rd day of the cycle and for 5 days and (combined pioglitazone 15 mg+ metformin 850 mg) once daily from the first day of the cycle for 10 days.
induction of ovulation using letrozole-pioglitazone-metformin: induction of ovulation was done for arm 1 for 3 consecutive cycles unless pregnancy occurred.
transvaginal ultrasound: transvaginal ultrasound will be done starting from day 10 and every 48 hours until finding a follicle of &gt; 18 mm or till day 20 of the cycle
body mass index (BMI) calculation: BMI was calculated.
day 3: follicle stimulating hormone (FSH), luteinizing hormone (LH), thyroid stimulating hormone (TSH), total testosterone: baseline hormonal assay (day 3 FSH, LH, TSH and total testosterone) were done for all women.
serum estradiol (E2) was done on day of hCG administration for all women.
serum progesterone on day 21 was done for all women.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Clomiphene Citrate-pioglitazone-metformin</title>
            <description>Arm 2 received clomiphene citrate 100 mg/day starting from the 3rd day of the cycle for 5 days and (combined pioglitazone 15 mg + metformin 850 mg) once daily from the first day of the cycle for 10 days.
induction of ovulation using clomiphene citrate-pioglitazone-metformin: induction of ovulation for arm 2 was done in 3 consecutive cycles unless pregnancy occurred.
transvaginal ultrasound: transvaginal ultrasound was done starting from day 10 and every 48 hours until finding a follicle of &gt; 18 mm or till day 20 of the cycle
body mass index (BMI) calculation: BMI was calculated.
day 3: follicle stimulating hormone (FSH), luteinizing hormone (LH), thyroid stimulating hormone (TSH), total testosterone: baseline hormonal assay (day 3 FSH, LH, TSH and total testosterone) were done for all women.
serum estradiol (E2) was done on day of hCG administration for all women.
serum progesterone on day 21 was done for all women.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Follicles&gt;18mm.</title>
          <units>follicles</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.44" spread="0.16"/>
                    <measurement group_id="O2" value="1.5" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endometrial Thickness</title>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1:Letrozole-pioglitazone -Metformin Group</title>
            <description>Arm 1 received letrozole 2.5 mg/day starting from the 3rd day of the cycle and for 5 days and (combined pioglitazone 15 mg+ metformin 850 mg) once daily from the first day of the cycle for 10 days.
induction of ovulation using letrozole-pioglitazone-metformin: induction of ovulation was done for arm 1 for 3 consecutive cycles unless pregnancy occurred.
transvaginal ultrasound: transvaginal ultrasound will be done starting from day 10 and every 48 hours until finding a follicle of &gt; 18 mm or till day 20 of the cycle
body mass index (BMI) calculation: BMI was calculated.
day 3: follicle stimulating hormone (FSH), luteinizing hormone (LH), thyroid stimulating hormone (TSH), total testosterone: baseline hormonal assay (day 3 FSH, LH, TSH and total testosterone) were done for all women.
serum estradiol (E2) was done on day of hCG administration for all women.
serum progesterone on day 21 was done for all women.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Clomiphene Citrate-pioglitazone-metformin</title>
            <description>Arm 2 received clomiphene citrate 100 mg/day starting from the 3rd day of the cycle for 5 days and (combined pioglitazone 15 mg + metformin 850 mg) once daily from the first day of the cycle for 10 days.
induction of ovulation using clomiphene citrate-pioglitazone-metformin: induction of ovulation for arm 2 was done in 3 consecutive cycles unless pregnancy occurred.
transvaginal ultrasound: transvaginal ultrasound was done starting from day 10 and every 48 hours until finding a follicle of &gt; 18 mm or till day 20 of the cycle
body mass index (BMI) calculation: BMI was calculated.
day 3: follicle stimulating hormone (FSH), luteinizing hormone (LH), thyroid stimulating hormone (TSH), total testosterone: baseline hormonal assay (day 3 FSH, LH, TSH and total testosterone) were done for all women.
serum estradiol (E2) was done on day of hCG administration for all women.
serum progesterone on day 21 was done for all women.</description>
          </group>
        </group_list>
        <measure>
          <title>Endometrial Thickness</title>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.56" spread="1.79"/>
                    <measurement group_id="O2" value="9.68" spread="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pregnancy Rate</title>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1:Letrozole-pioglitazone -Metformin Group</title>
            <description>Arm 1 received letrozole 2.5 mg/day starting from the 3rd day of the cycle and for 5 days and (combined pioglitazone 15 mg+ metformin 850 mg) once daily from the first day of the cycle for 10 days.
induction of ovulation using letrozole-pioglitazone-metformin: induction of ovulation was done for arm 1 for 3 consecutive cycles unless pregnancy occurred.
transvaginal ultrasound: transvaginal ultrasound will be done starting from day 10 and every 48 hours until finding a follicle of &gt; 18 mm or till day 20 of the cycle
body mass index (BMI) calculation: BMI was calculated.
day 3: follicle stimulating hormone (FSH), luteinizing hormone (LH), thyroid stimulating hormone (TSH), total testosterone: baseline hormonal assay (day 3 FSH, LH, TSH and total testosterone) were done for all women.
serum estradiol (E2) was done on day of hCG administration for all women.
serum progesterone on day 21 was done for all women.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Clomiphene Citrate-pioglitazone-metformin</title>
            <description>Arm 2 received clomiphene citrate 100 mg/day starting from the 3rd day of the cycle for 5 days and (combined pioglitazone 15 mg + metformin 850 mg) once daily from the first day of the cycle for 10 days.
induction of ovulation using clomiphene citrate-pioglitazone-metformin: induction of ovulation for arm 2 was done in 3 consecutive cycles unless pregnancy occurred.
transvaginal ultrasound: transvaginal ultrasound was done starting from day 10 and every 48 hours until finding a follicle of &gt; 18 mm or till day 20 of the cycle
body mass index (BMI) calculation: BMI was calculated.
day 3: follicle stimulating hormone (FSH), luteinizing hormone (LH), thyroid stimulating hormone (TSH), total testosterone: baseline hormonal assay (day 3 FSH, LH, TSH and total testosterone) were done for all women.
serum estradiol (E2) was done on day of hCG administration for all women.
serum progesterone on day 21 was done for all women.</description>
          </group>
        </group_list>
        <measure>
          <title>Pregnancy Rate</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Safety of Pioglitazone as Regards Serum Creatinine</title>
        <description>serum creatinine was measured at the end of the study period (after 3 months) in both groups.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1:Letrozole-pioglitazone -Metformin Group</title>
            <description>Arm 1 received letrozole 2.5 mg/day starting from the 3rd day of the cycle and for 5 days and (combined pioglitazone 15 mg+ metformin 850 mg) once daily from the first day of the cycle for 10 days.
induction of ovulation using letrozole-pioglitazone-metformin: induction of ovulation was done for arm 1 for 3 consecutive cycles unless pregnancy occurred.
transvaginal ultrasound: transvaginal ultrasound will be done starting from day 10 and every 48 hours until finding a follicle of &gt; 18 mm or till day 20 of the cycle
body mass index (BMI) calculation: BMI was calculated.
day 3: follicle stimulating hormone (FSH), luteinizing hormone (LH), thyroid stimulating hormone (TSH), total testosterone: baseline hormonal assay (day 3 FSH, LH, TSH and total testosterone) were done for all women.
serum estradiol (E2) was done on day of hCG administration for all women.
serum progesterone on day 21 was done for all women.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Clomiphene Citrate-pioglitazone-metformin</title>
            <description>Arm 2 received clomiphene citrate 100 mg/day starting from the 3rd day of the cycle for 5 days and (combined pioglitazone 15 mg + metformin 850 mg) once daily from the first day of the cycle for 10 days.
induction of ovulation using clomiphene citrate-pioglitazone-metformin: induction of ovulation for arm 2 was done in 3 consecutive cycles unless pregnancy occurred.
transvaginal ultrasound: transvaginal ultrasound was done starting from day 10 and every 48 hours until finding a follicle of &gt; 18 mm or till day 20 of the cycle
body mass index (BMI) calculation: BMI was calculated.
day 3: follicle stimulating hormone (FSH), luteinizing hormone (LH), thyroid stimulating hormone (TSH), total testosterone: baseline hormonal assay (day 3 FSH, LH, TSH and total testosterone) were done for all women.
serum estradiol (E2) was done on day of hCG administration for all women.
serum progesterone on day 21 was done for all women.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety of Pioglitazone as Regards Serum Creatinine</title>
          <description>serum creatinine was measured at the end of the study period (after 3 months) in both groups.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.62" spread="0.04"/>
                    <measurement group_id="O2" value="0.57" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm 1:Letrozole-pioglitazone -Metformin Group</title>
          <description>Arm 1 received letrozole 2.5 mg/day starting from the 3rd day of the cycle and for 5 days and (combined pioglitazone 15 mg+ metformin 850 mg) once daily from the first day of the cycle for 10 days.
induction of ovulation using letrozole-pioglitazone-metformin: induction of ovulation was done for arm 1 for 3 consecutive cycles unless pregnancy occurred.
transvaginal ultrasound: transvaginal ultrasound will be done starting from day 10 and every 48 hours until finding a follicle of &gt; 18 mm or till day 20 of the cycle
body mass index (BMI) calculation: BMI was calculated.
day 3: follicle stimulating hormone (FSH), luteinizing hormone (LH), thyroid stimulating hormone (TSH), total testosterone: baseline hormonal assay (day 3 FSH, LH, TSH and total testosterone) were done for all women.
serum estradiol (E2) was done on day of hCG administration for all women.
serum progesterone on day 21 was done for all women.</description>
        </group>
        <group group_id="E2">
          <title>Arm 2: Clomiphene Citrate-pioglitazone-metformin</title>
          <description>Arm 2 received clomiphene citrate 100 mg/day starting from the 3rd day of the cycle for 5 days and (combined pioglitazone 15 mg + metformin 850 mg) once daily from the first day of the cycle for 10 days.
induction of ovulation using clomiphene citrate-pioglitazone-metformin: induction of ovulation for arm 2 was done in 3 consecutive cycles unless pregnancy occurred.
transvaginal ultrasound: transvaginal ultrasound was done starting from day 10 and every 48 hours until finding a follicle of &gt; 18 mm or till day 20 of the cycle
body mass index (BMI) calculation: BMI was calculated.
day 3: follicle stimulating hormone (FSH), luteinizing hormone (LH), thyroid stimulating hormone (TSH), total testosterone: baseline hormonal assay (day 3 FSH, LH, TSH and total testosterone) were done for all women.
serum estradiol (E2) was done on day of hCG administration for all women.
serum progesterone on day 21 was done for all women.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ghada Abdel Fattah</name_or_title>
      <organization>Cairo University</organization>
      <phone>00201006513305</phone>
      <email>ghadaabdelfatah2007@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

